The TAT congress is the premier forum for discussion of early phase drug development and translational research.

Leaders from academia and industry, clinicians, researchers and regulators work together to speed up the development of new anti-cancer treatments for better patient outcomes.

The TAT Congress series has been at the forefront of revolutionary transformation in early drug development and has succeeded in broadening the conversation on phase I trials to include a wide circle of stakeholders.